AZA-PD: Azathioprine for Parkinson’s
AZA-PD was a phase 2 clinical trial of azathioprine – an immunosuppressant medication – to evaluate its safety and ability to lower neuroinflammation in people with Parkinson’s. Contents About the study Dr Caroline Williams-Gray at the University of Cambridge led a phase 2 clinical trial...
Exenatide-PD3: Exenatide and Parkinson’s
The Exenatide-PD3 study was a phase 3 clinical trial of Type 2 diabetes drug exenatide (Bydureon) which finished in early 2024. The results of this trial have now been published and they indicate that the study did not slow the progression of Parkinson’s compared to...
The UP Study: UDCA and Parkinson’s
The UP Study, or UDCA for Parkinson’s Study, was a phase 2 clinical trial which aimed to assess the safety and tolerability of ursodeoxycholic acid (UDCA) in people with Parkinson’s. Contents About the study Led by Professor Oliver Bandmann at the University of Sheffield, this...
Repurposing anti-gout medication for Parkinson’s
The goal of this preclinical study was to determine whether two anti-gout medications could slow progression in models of Parkinson’s. Contents About the study Professor Heather Mortiboys at the University of Sheffield conducted an 18-month preclinical study on two anti-gout medications to determine their potential...
Genetic Storage for Parkinson’s
This study aimed to create a biobank for UK clinical trials involving people with Parkinson’s, with a focus on providing genetic sequencing for researchers. Contents About the study For the majority of people with Parkinson’s, the cause of the condition is not well understood, and...